Nkarta

Update in progress

NKTX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Nkarta, Inc. is a clinical-stage biopharma company developing natural killer (NK) cell therapies for cancer and autoimmune diseases. Its lead candidate, NKX019, is a CAR-NK therapy targeting CD19 and is in Phase 1 testing for lupus nephritis, systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, systemic lupus erythematosus, and myasthenia gravis. The company collaborates with CRISPR Therapeutics and is based in South San Francisco, founded in 2015.

Company score

Sentiment: 0.14; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.04; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.07; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive